Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosentyx in moderate-to-severe hidradenitis suppurativa
NCT03099980Phase 1Completed
- Sponsor
- Tufts Medical Center
- Start
- Jul 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of secukinumab in hidradenitis suppurativa (HS), sponsored by Tufts Medical Center. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03099980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099980.